Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vutiglabridin
- Development stage
- Phase 2
- Lead developer
- Glaceum
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vutiglabridin is an experimental anti-obesity drug and a synthetic structural analog of glabridin. It is being developed by Glaceum for obesity and Parkinson's disease. Vutiglabridin acts as an inflammation mediator inhibitor, metabolism stimulant, and triglyceride modulator. It has shown therapeutic effects on mitochondrial paraoxonase-2 (PON2) in Parkinson's disease models.
- Brand names
- vutiglabridin
- Other names
- HSG4112HSG-4112HSG 4112
02
Targets
PON2 (Paraoxonase 2)PON1 (Paraoxonase 1)
Beyond the preview
Go deeper on vutiglabridin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vutiglabridin.